The company’s loss from operations was $18.67m, compared to $6.47m for the same period last year.
Total operating expenses for the first quarter ended 31 March 2011 were $18.7m, as compared to $6.5m for the same period in 2010.
Anthera Pharmaceuticals is a biopharmaceutical company engaged in developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.